Ivax acquires two Elan products
Executive Summary
Ivax is acquiring Elan's marketed intranasal flunisolide products Nasarel and Nasalide, indicated for treatment of seasonal and perennial allergic rhinitis
You may also be interested in...
Qvar Sales Reps Grow To 200; Ivax Sees Outlicensing Opportunities From R&D
Ivax will have 200 sales reps to promote Qvar and its other respiratory products by the end of the year, President Neil Flanzraich said in Ivax's third quarter conference call Oct. 29
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011